Alidhe
A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy
Description: The purpose of this study is to learn more about the safety and efficacy of the medication ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a particular gene mutation called IDH1 (isocitrate dehydrogenase1)
Study Phase: Phase 3
Principal Investigator: Dr Nina Orfali
Further information